Runda Medical disclosed its 2026 half-year report on the evening of August 27. During the reporting period, the company achieved operating revenue of 3.194 billion yuan, with non-GAAP net profit improving 39.86% year-on-year. The non-GAAP loss narrowed significantly, and net cash flow from operating activities rebounded sharply. Against the backdrop of overall industry pressure, the company narrowed its second-quarter single-quarter loss by 35.95% compared with the first quarter through business structure optimization, showing marginal improvement in operating fundamentals. In the first half of the year, Runda Medical's industrial segment achieved operating revenue of 265 million yuan, up 26.18% year-on-year, mainly benefiting from the continued rapid growth of its core self-produced glycated testing products. The company further advanced the overseas commercialization of glycated products. Its two core glycated products, MQ-8000/8000PT and MQ-3000/3000PT, both obtained FDA certification. In the first half of the year, overseas revenue from glycated products reached 68 million yuan, up 80% year-on-year. The company also continued to enrich its proprietary product pipeline around glycation, mass spectrometry, biochemistry, POCT and other technology fields, building momentum for the subsequent growth of its industrial segment.
Shanghai Runda Med Tech CoH1 non-GAAP net profit improved 39.86% YoY and Q2 loss narrowed 35.95% QoQ, showing improved operating fundamentals.
